- Conditions
- Idiopathic Pulmonary Fibrosis
- Interventions
- EGCG 300 mg + Nintedanib, EGCG 300 mg + Pirfenidone, Placebo 2 capsules + Nintedanib or Pirfenidone, EGCG 600 mg + Nintedanib, EGCG 600 mg + Pirfenidone, Placebo 4 capsules + Nintedanib or Pirfenidone
- Combination Product
- Lead sponsor
- Hal Chapman
- Other
- Eligibility
- 40 Years to 85 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 7
- States / cities
- San Francisco, California • Boston, Massachusetts • Ann Arbor, Michigan + 4 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–2
of 2
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Idiopathic Pulmonary Fibrosis
- Interventions
- EGCG 300 mg, Placebo for EGCG 300 mg, EGCG 600 mg, Placebo for EGCG 600 mg
- Drug
- Lead sponsor
- Hal Chapman
- Other
- Eligibility
- 40 Years to 85 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 3
- States / cities
- Boston, Massachusetts • Ann Arbor, Michigan • Charlottesville, Virginia